niacinamide has been researched along with Parkinsonian Disorders in 4 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Parkinsonian Disorders: A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Harrison, IF | 1 |
| Powell, NM | 1 |
| Dexter, DT | 1 |
| Anderson, DW | 2 |
| Bradbury, KA | 2 |
| Schneider, JS | 2 |
| Jia, H | 1 |
| Li, X | 2 |
| Gao, H | 1 |
| Feng, Z | 1 |
| Zhao, L | 1 |
| Jia, X | 1 |
| Zhang, H | 1 |
| Liu, J | 1 |
4 other studies available for niacinamide and Parkinsonian Disorders
| Article | Year |
|---|---|
The histone deacetylase inhibitor nicotinamide exacerbates neurodegeneration in the lactacystin rat model of Parkinson's disease.
Topics: Acetylation; Acetylcysteine; Animals; Cell Death; Disease Models, Animal; Dopaminergic Neurons; Hist | 2019 |
Broad neuroprotective profile of nicotinamide in different mouse models of MPTP-induced parkinsonism.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Humans; | 2008 |
Neuroprotection in Parkinson models varies with toxin administration protocol.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antigens, Nuclear; Axons; Benzothiazoles; Bio | 2006 |
High doses of nicotinamide prevent oxidative mitochondrial dysfunction in a cellular model and improve motor deficit in a Drosophila model of Parkinson's disease.
Topics: alpha-Synuclein; Animals; Animals, Genetically Modified; Cell Line, Tumor; Cell Survival; Disease Mo | 2008 |